A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists
Journal of Medicinal Chemistry2004Vol. 47(27), pp. 6662–6665
Citations Over TimeTop 15% of 2004 papers
Jeffrey J. Hale, Christopher L. Lynch, William Neway, Sander G. Mills, Richard Hajdu, Carol Keohane, Mark Rosenbach, James A. Milligan, Gan-Ju Shei, Stephen A. Parent, Gary Chrebet, James D. Bergstrom, Deborah Card, Marc Ferrer, Peter Hodder, Berta Strulovici, Hugh Rosen, Suzanne Mandala
Abstract
Moderately potent, selective S1P(1) receptor agonists identified from high-throughput screening have been adapted into lipophilic tails for a class of orally bioavailable amino acid-based S1P(1) agonists represented by 7. Many of the new compounds are potent S1P(1) agonists that select against the S1P(2), S1P(3), and S1P(4) (although not S1P(5)) receptor subtypes. Analogues 18 and 24 are highly orally bioavailable and possess excellent pharmacokinetic profiles in the rat, dog, and rhesus monkey.
Related Papers
- → Enhancement of Neoangiogenesis and Follicle Survival by Sphingosine-1-Phosphate in Human Ovarian Tissue Xenotransplants(2011)198 cited
- → Sphingosine-1–Phosphate, FTY720, and Sphingosine-1–Phosphate Receptors in the Pathobiology of Acute Lung Injury(2013)146 cited
- → Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis(2012)20 cited
- Analysis of a Sphingosine 1-phosphate Receptor $hS1P_3$ in Rat Hepatoma Cells(2002)
- → The sphingosine-1-phosphate receptor agonist FTY720 promotes peripheral nerve regeneration(2014)